Pharmacovigilance (PV) inspection should begin even before a health authority plans a visit. Inspection readiness relies heavily on an existing quality system, accurate and periodic documentation, and clear ownership of safety responsibilities throughout the organization.
Read MorePost-market surveillance (PMS) is the central aspect of MDR compliance. It gives the device manufacturer a structured way to monitor device safety and performance in real-world use throughout the device lifecycle. The device manufacturer can
Read MoreDeveloping a global regulatory strategy for a new drug means planning early for the markets you want to enter. It involves gathering the evidence each region expects and the submission sequence to reduce delays. A
Read MoreRegulatory inspections can feel unpredictable, but most findings follow similar tendencies across FDA, EMA, and DCGI reviews. A strong FDA inspection-readiness mindset is not about preparing for one visit; it is about building a system
Read More
Most companies don’t think about pharmacovigilance until they’re forced to. A product gets approved, the first adverse event report lands in someone’s inbox, and suddenly, there’s a scramble to figure out: who owns the process,
Read MoreAccelerated approval pathways are designed to bring important therapies to patients sooner, especially in serious or life-threatening diseases with unmet medical needs. For a regulatory service provider, the key value is helping sponsors choose the
Read More
Regulatory affairs has never exactly been a slow moving field. But 2026 feels different. Agencies that spent years cautiously watching AI from a distance are now actively deploying it. Real world evidence once a nice
Read MoreGiven the abundance of connected devices, cloud-linked systems, software-driven platforms, and their ability to pose direct risks to patient safety, data integrity, and product reliability, Cybersecurity has now become more than a compliance issue. From
Read MoreIndia’s pharmaceutical market continues to expand, and with the growth comes greater responsibility for drug safety oversight. The Central Drugs Standard Control Organization (CDSCO) plays a central role in shaping the country’s pharmacovigilance framework. Key
Read MoreIndia’s pharmaceutical sector is evolving from high-volume output to strategic global importance. The domestic market, currently USD 50–60 billion, is projected to reach USD 130 billion by 2030. With FY2026 growth forecasts of 7%–11%, India
Read More